AI-Native Operating Model
What the business becomes when AI is embedded, not bolted on
Current-state diagnosis, workflow redesign across the regulated functions (medical, commercial, clinical, network), governance design, tech-stack rationalization, and a board-ready roadmap.
How this work runs
Most AI work starts at the pilot. AI-Native Operating Model Design starts upstream. The work asks what should change in growth, decisions, governance, and review when AI is embedded in how the business runs, then turns the answer into a board-ready redesign.
When this fits
- A new CCO, CDO, CMO, Chief Health AI Officer, or Chief AI Officer took the seat in the last 6 to 12 months with a board-level AI mandate
- Pilots have stalled because the operating model never changed underneath them, whether at a pharma, payer, provider system, pharmacy, or med-device company
- Tech-stack fragmentation has reached the point where another point solution makes things worse
What you get
- End-to-end redesign across the regulated functions (medical, commercial, clinical, network) inside the chosen vertical
- Workflow redesign with explicit regulated-review and approval considerations (firewall and PV at a pharma, utilization management at a payer, clinical review at a provider, pharmacist review at a pharmacy)
- Tech-stack rationalization on the regulated × commercial axis specific to the vertical
- Board-ready roadmap with sequencing, owners, and decision rights
- Execution-ready sprint plan with resourcing, governance model, milestones, and communications plan